Candidate Compounds Covid19

(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
Zeile 1: Zeile 1:
 
{{pnc}}
 
{{pnc}}
 +
 +
*[[reviews on covid drug development]]
 +
*
 +
 +
*[[pre-Interleukin 6]]
 +
*[[post-Interleukin 6]]
 +
*[[pre-Interleukin 17]]
 +
*[[post-Interleukin 17]]
 +
*[[pre-TNFalpha]]
 +
*[[post-TMFalpha]]
 +
*[[NK-kappaB]]
 +
*[[STAT 3]]
 +
*[[Target Extracellular traps]]
 +
*[[Anticoagulant in covid19]]
 +
*[[Antioxidants]]
 +
*[[Stem cells]]
 +
*[[MDSC cells]]
 +
 +
 +
 +
*
 +
*[[Hydroxychloroquine]]
 +
*
 +
 +
*[[AV Remdesivir]]
 +
*[[AV Lopinavir]]
 +
*[[AV Ivermectin]]
 +
*[[Interferons]]
 +
*[[Vitamin D]]
 +
 +
*[[Statins]]
 +
*[[Anorganic nutrients Magnesium]]
 +
*[[Anorganic nutrients Selenium]]
 +
*[[Anorganic nutrients Zinc]]
 +
 +
 +
 +
*[[Traditional Chinese Medicine]]
 +
*[[Natural compounds]]
 +
*[[Retargeted single compounds]]
 +
 +
*[[Target ACE2, Spike protein]]
 +
*[[Target TMPRSS2, Spike protein]]
 +
*[[Reconvalescent blood products, Passive vaccine]]
 +
*[[Plasmapheresis]]
 +
 +
 +
*[[Active vaccine]]
  
 
'''reviews & screen candidate compounds covid19'''
 
'''reviews & screen candidate compounds covid19'''
Zeile 174: Zeile 222:
  
 
'''Anticoagulants'''
 
'''Anticoagulants'''
−
*[[Anticoagulant in covid19]]
+
 
  
 
'''Vaccination Covid19'''
 
'''Vaccination Covid19'''

Version vom 28. Mai 2020, 07:21 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.




reviews & screen candidate compounds covid19
32226821 2020. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
32292689 ä. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
32318328 ä. D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19
32152082 2020. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus
32232214 2020. Potential Treatments for COVID-19; a Narrative Literature Review
32134278 2020. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)
32375268 2020. Coronavirus Pandemic-Therapy and Vaccines
31996494 2020. Drug treatment options for the 2019-new coronavirus (2019-nCoV)
32334062 ä. Current status of potential therapeutic candidates for the COVID-19 crisis
32347359 ä. Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19
32162456 2020. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1 3 Billion Compounds
32194980 2020. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
32149769 ä. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model


Icatibant bradykinin antagonist
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications

Arbidol retarget influenza
32373347 2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro

Macrolide antibiotics
32249257 2020. Macrolide treatment for COVID-19: Will this be the way forward?

Oleoylethanolamide
32327293 ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19

Metronidazole retarget
32259129 2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen

Glutathione GSH antioxidant

Chlorpromazine retarget

Zinc add-on

Selenium
32342979 ä. Association between regional selenium status and reported outcome of COVID-19 cases in China

Remdesivir retarget


32283108 ä. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
32020029 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Lauric acid nat. compd.

Nicotine nat. toxin

Niclosamide
32125140 ä. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential

Microbiome as target
32356654 ä. Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles

ACE2 as target
32286790 ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2
32333836 ä. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2


Garlic extracts
32363255 ä. Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil

Dipyridamole retarget
32318327 ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

stem cells
32257554 2020. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia
32257537 2020. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
32283815 2020. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use


Ivermectin
32330482 ä. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors responses

Various Leads


32251767 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro


Interferons
32275914 2020. Type 1 interferons as a potential treatment against COVID-19
32360182 2020. Antiviral activities of type I interferons to SARS-CoV-2 infection

Plasmapheresis

Reconvalescent sera
32243945 ä. Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection

Therapeutic antibodies (virus-targeted)


32375025 ä. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies

Therapeutic antibodies and biologicals (cytokine/sugnal transduction)
32247642 ä. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report
32241793 2020. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
32243501 2020. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
32343968 ä. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report

Glucocorticoids


32149773 ä. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial

CRISPR genome editing technology
32353252 ä. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza

Virus interference
32071427 2020. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses

Other antirheumatic compounds

Hydroxy-Chloroquine


32232419 ä. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know
32227189 ä. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19
32147496 2020. Of chloroquine and COVID-19
32074550 2020. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
32321905 2020. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
32281583 2020. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)
32265182 2020. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review
32194981 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Chemoprevention Covid19

Antiviral agents Covid19
32231345 2020. Inhibition of SARS-CoV-2 (previously 2019-nCoV)infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Lung regeneration and repair after Covid19

resilience enhancement
32229705 2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections
32311498 ä. The impact of nutrition on COVID-19 susceptibility and long-term consequences
32276453 2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats

psychoneuroimmunology
32234338 ä. Using psychoneuroimmunity against COVID-19

cannabinoids
32360437 ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?


Complementary & Traditional chinese medicine & Ethnopharm
32245701 ä. Is traditional Chinese medicine useful in the treatment of COVID-19?
32233641 2020. Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19


32229706 2020. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
32037389 2020. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment
32334064 ä. Ayurveda and COVID-19: where psychoneuroimmunology and the meaning response meet
32361935 ä. Traditional Chinese and Western Medicines Jointly Beat COVID-19 Pandemic
32065348 ä. Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs
32308732 2020. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China

Exercise
32311497 ä. The immunological case for staying active during the COVID-19 pandemic

Topical agents opening up the world of nano...

Anticoagulants


Vaccination Covid19
32105090 2020. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic


32183941 2020. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2



32371558 2020. Hydroxychloroquine use in the COVID-19 patient
32272008 2020. Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2
32337664 ä. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
32359035 2020. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19
32272196 2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology
32247038 2020. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19
32222466 2020. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China
32360516 ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
32353634 2020. COVID-19: Immunology and treatment options
32335290 2020. A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection
32150618 ä. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
32211771 ä. Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?
32211764 ä. Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to Healthcare Workers Exposed to Coronavirus Disease 2019?
32266375 ä. Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 mortality
32255489 ä. Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients
32301957 ä. Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19


32344167 ä. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study
32305181 ä. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection
32360083 ä. Modulation of Hb-O2 affinity to improve hypoxemia in COVID-19 patients
32306288 ä. Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties
32277367 ä. Rheumatologists? perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets
32373721 2020. Low dose lung radiotherapy for COVID-19 pneumonia The rationale for a cost-effective anti-inflammatory treatment
32269021 2020. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection
32209231 2020. Computers and viral diseases Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus
32264963 2020. A new clinical trial to test high-dose vitamin C in patients with COVID-19
32280433 ä. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
32345336 2020. Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2
32351851 ä. A Coronavirus Disease 2019 (COVID-19) Patient with Multifocal Pneumonia Treated with Hydroxychloroquine
32241301 2020. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)
32318324 ä. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival
32340837 ä. Hydroxychloroquine in Covid-19: Does the end justify the means?
32219057 ä. The SARS-CoV-2 Vaccine Pipeline: an Overview
32360420 ä. Cytokine storm intervention in the early stages of COVID-19 pneumonia


32337328 2020. Coronaviruses: A patent dataset report for research and development (R&D) analysis
32247211 2020. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries
32335366 2020. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis
32333972 ä. Letter to the Editor in response to the article ?COVID-19 and diabetes: Can DPP4 inhibition play a role??
32333966 2020. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications
32333969 ä. Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? ? GLP-1 Might Play One Too
32283128 ä. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? on ace2 via adam17, nfkb via dpp4
32309622 ä. Emerging Therapeutic Strategies for COVID-19 patients
32336723 2020. Treatment of SARS-CoV-2: How far have we reached?
32321878 2020. Is GSK3beta a molecular target of chloroquine treatment against COVID-19?
32378648 2020. Rapid review for the anti-coronavirus effect of remdesivir
32378647 2020. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
32147628 2020. Discovering drugs to treat coronavirus disease 2019 (COVID-19)
32371138 ä. Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19
32198066 ä. Advance of promising targets and agents against COVID-19 in China
32325124 ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals
32320852 ä. Deja vu: Stimulating open drug discovery for SARS-CoV-2
32304645 ä. Boosting the arsenal against COVID-19 through computational drug repurposing
32266694 ä. Chloroquine for COVID-19 Infection
32373183 2020. Chloroquine and hydroxychloroquine in the context of COVID-19
32343658 2020. Medication for COVID-19-an Overview of Approaches Currently Under Study
32344202 2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
32249203 ä. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development


32379923 2020. Is BCG vaccination causally related to reduced COVID-19 mortality?
32333818 2020. COVID-19: lambda interferon against viral load and hyperinflammation
32338155 2020. Rheumotologitsts view on the use of hydroxychloroquine to treat COVID-19
32228222 2020. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
32148172 2020. Timely development of vaccines against SARS-CoV-2
C7118608 ä. A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System
32065055 2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
32346491 ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
32292627 ä. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment


32363880 2020. Medical treatment options for COVID-19
32372695 2020. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol
32347925 ä. Statin therapy in COVID-19 infection
32347923 ä. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety
32337546 ä. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?
32282032 ä. Neprilysin inhibitor?angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients
32285293 ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV
C7129866 ä. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19
32341100 2020. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective
32265310 ä. Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19
32271462 2020. Inositol and pulmonary function Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?
32271456 2020. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019
32271454 2020. Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19
32329881 2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience
32329879 2020. (Naturlal products: )An alternative approach to minimize the risk of coronavirus (Covid-19) and similar infections
32327396 ä. COVID-19 and Bacillus Calmette-Guerin: What is the Link?
32279655 2020. Can Hepatitis A Vaccine Provide Protection Against COVID-19?
32250170 2020. Will plant-made biopharmaceuticals play a role in the fight against COVID-19?
32329380 2020. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia
32312129 2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic
32117569 2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China
32212513 2020. The Trial of Chloroquine in the Treatment of Corona Virus Disease 2019 COVID-19 and Its Research Progress in Forensic Toxicology
32269766 2020. In silico identification of vaccine targets for 2019-nCoV


32374074 2020. Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease
32265848 2020. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
32363145 ä. An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine
32363144 ä. Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin


32247692 ä. Faecal-oral transmission of SARS-COV-2: practical implications
32367287 ä. New evidence of SARS-CoV-2 transmission through the ocular surface
32363144 ä. Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin
32251729 ä. The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design
32313872 ä. COVID-19 convalescent plasma transfusion
32251365 ä. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy
32375153 2020. HMGB1: A Possible Crucial Therapeutic Target for COVID-19?
32186952 2020. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics
32341910 2020. SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis
32300370 2020. Can an effective SARS-CoV-2 vaccine be developed for the older population?
32259480 ä. SARS-CoV-2 Vaccines: Status Report
32362644 2020. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use
32317408 2020. Perspectives for repurposing drugs for the coronavirus disease 2019
32317405 2020. Tracking the impact of interventions against COVID-19 in absence of extensive testing
32201449 2020. Drug targets for corona virus: A systematic review
32278018 ä. Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society
32366728 2020. Medical Education During the COVID-19 Pandemic: A Single Institution Experience
32366726 2020. Management of Asthma in Children during COVID-19 Pandemic
32366725 2020. COVID -19 Pandemic: The Challenges for Pediatric Oncology
32358227 2020. Demystifying BCG Vaccine and COVID-19 Relationship
32291382 2020. Coronavirus Vaccines: Light at the End of the Tunnel
32238614 2020. Measles Immunization: Worth Considering Containment Strategy for SARS-CoV-2 Global Outbreak
32321620 ä. Corticosteroid use for 2019-nCoV infection: A double-edged sword
32341599 2020. Is Immuno-modulation the Key to COVID-19 Pandemic?


32320825 ä. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
32328406 ä. Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains
32335561 2020. Update on treatment of COVID-19: ongoing studies between promising and disappointing results
32335560 2020. Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives - A better synergy for future COVID-19 clinical trials
32342098 ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib
32372149 ä. SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?
32352026 2020. Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach
32272396 ä. The Possible of Immunotherapy for COVID-19: a Systematic Review
32311668 ä. SARS-Cov-2 infection: response of human immune system and possible implications for the rapid test and treatment
32234467 ä. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality
32234466 ä. Coronavirus disease 2019 (COVID-19): current status and future perspectives
32205204 ä. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
32171740 ä. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
32070753 2020. Chloroquine for the 2019 novel coronavirus SARS-CoV-2
32278811 ä. Drug repositioning is an alternative for the treatment of coronavirus COVID-19
32259575 ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19
32361028 ä. ?Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ?
32251732 ä. Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage
32251731 ä. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
32360231 ä. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?
32335281 ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19
32305589 ä. Combating Devastating COVID -19 by Drug Repurposing
32305588 ä. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies
32298745 ä. Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection
C7152897 ä. Chloroquine as prophylactic agent against COVID-19?
32283177 ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections
32194152 ä. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine
32179150 ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?
32147516 ä. Arguments in favour of remdesivir for treating SARS-CoV-2 infections
32145363 2020. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
32363157 2020. Chloroquine: Can it be a Novel Drug for COVID-19
32226290 2020. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19
32226288 2020. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective
32226289 2020. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
32300868 ä. Balneotherapy and human immune function in the era of COVID-19
32321655 ä. An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients
32251768 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro


32305009 ä. Investigating hypothiocyanite against SARS-CoV-2
32173576 2020. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression
32218340 2020. Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?
32354030 2020. Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work
32325767 2020. COVID-19 Drug Discovery Using Intensive Approaches
32353978 2020. Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design


32368489 2020. The pathogenesis and alternative treatment of SARS-CoV2
32289016 2020. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines
32125455 ä. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
32347443 ä. Camostat mesilate therapy for COVID-19
32333086 ä. Remdesivir bei Patienten mit schwerer COVID-19
32378817 2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients


32283237 ä. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?
32278797 ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2
32348818 ä. Risks of Hydroxychloroquine use for COVID-19 prophylaxis
32339701 ä. Potential role of Janus kinase inhibitors in COVID-19
32344070 ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19
32283236 ä. Does hydroxychloroquine combat COVID-19? A timeline of evidence


32330546 ä. Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated with Hydroxychloroquine and/or Azithromycin
32283123 ä. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment
32336674 ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research
32361744 ä. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease
32196083 ä. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression
32317220 ä. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
32291137 ä. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
32284326 2020. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
32094225 2020. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
32295479 2020. Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study
32306862 2020. Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes
32266873 2020. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2?-O-ribose methyltransferase
32238078 2020. In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel


32374474 2020. Natural antiviral compound silvestrol modulates human monocyte-derived macrophages and dendritic cells
32281268 2020. G6PD and chloroquine: Selecting the treatment against SARS?CoV?2?
32255648 ä. A Community Letter Regarding Sharing Biomolecular Simulation Data for COVID-19
32315171 ä. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study
32243270 2020. Potential therapeutic agents against COVID-19: What we know so far
32254064 2020. Deployment of convalescent plasma for the prevention and treatment of COVID-19
32352407 2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists
32167489 ä. The convalescent sera option for containing COVID-19
32326602 2020. Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19
32326426 2020. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with beta-Cyclodextrin Combined with Citrox in Preventing Infection and Progression


32353761 2020. Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review
32305026 ä. Challenges of Convalescent Plasma Therapy on COVID-19
32314081 ä. Pharmacologic Therapy for COVID-19 Infection
32289152 2020. COVID-19 and emerging viral infections: The case for interferon lambda
32302401 2020. Targeting potential drivers of COVID-19: Neutrophil extracellular traps
32359878 2020. Application of plasma exchange in association with higher dose CVVH in Cytokine Storm Complicating COVID-19


32171450 2020. Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus
32173287 ä. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines
32373322 ä. Fighting COVID-19 with water dehydration of mucous glycans
32372051 ä. Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2
32335161 ä. In the search of potential epitopes for Wuhan seafood market pneumonia virus using high order nullomers
32300051 2020. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
32171872 ä. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
32333918 ä. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
32283153 ä. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1
32362440 ä. Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases
32232474 ä. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure
32348485 ä. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients
32348489 ä. COVID-19: Is Everything Appropriate to Create an Effective Vaccine?


32293807 2020. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID?19: initial assessment
32307268 2020. Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC?MSE analysis
32122812 2020. Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2)
32113846 ä. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus
32080993 2020. The Author s Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
32080992 2020. Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
32056407 2020. Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
32281317 2020. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea
32356252 ä. COVID-19: Therapeutics and Their Toxicities
32356251 ä. Medical Toxicology and COVID-19: Our Role in a Pandemic
32052466 2020. Potential interventions for novel coronavirus in China: A systematic review
32022276 2020. Immunoinformatics?aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019?nCoV

32249185 ä. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection
32205092 ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib


32307245 ä. Treatment options for COVID-19: The reality and challenges
32331982 ä. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
32236561 ä. Combating COVID-19 with Chloroquine
32361836 ä. CNS penetration of potential anti-COVID-19 drugs
32296570 ä. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants?
32346490 ä. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase
32324533 2020. Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients
32251618 2020. Current Drugs with Potential for Treatment of COVID-19: A Literature Review
32291198 2020. Impact of Nutrition and Diet on COVID-19 Infection and Implications for Kidney Health and Kidney Disease Management


32353597 ä. SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy
32281481 2020. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review
32370758 2020. SARS-CoV-2 RNA polymerase as target for antiviral therapy
C7154570 2020. Anti-IL6R role in treatment of COVID-19-related ARDS
32290839 2020. Why tocilizumab could be an effective treatment for severe COVID-19?
32313848 ä. Precision medicine in COVID-19: IL-1 beta a potential target
32219428 2020. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
32356863 ä. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)
32356858 ä. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit
32330277 2020. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial
32339248 2020. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial
32374264 2020. Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point
32321635 2020. Old and new antirheumatic drugs for the treatment of COVID-19
32321634 2020. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome

Von „http://coviki.org/cov/index.php?title=Candidate_Compounds_Covid19&oldid=1564“
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis